N@N

China Aoxing Pharmaceutical Co., Inc.: China Aoxing Pharmaceutical Company to Present at Two Institutional Conferences in the U

_{//health-fitness.news-articles.net/content/2009/ .. t-at-two-institutional-conferences-in-the-u.html}
^{Published in Health and Fitness on Friday, May 8th 2009 at 5:08 GMT, Last Modified on 2009-11-02 13:00:57 by Market Wire}  

NEW YORK, NY--(Marketwire - May 8, 2009) - China Aoxing Pharmaceutical Company, Inc. (OTCBB: [ CAXG ]) ("China Aoxing" or the "Company"), a pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products, today announced the Company's participation in the following conferences:

 -- Oppenheimer 3rd Annual China Dragon Call Conference, held May 19-21 at 300 Madison Avenue in New York City. Management is currently scheduled to meet with institutional investors and to present from 11:25 am to 11:55 am (EDT) on May 19; -- JMP 8th Annual Research Conference, held May 18-20, 2009 at the Ritz- Carlton in San Francisco. Management is currently scheduled to meet with institutional investors and to present at 10:30 am to 11:00 am (Pacific Time) on May 20. 

For further details, please contact your institutional sales representative.

About China Aoxing Pharmaceutical Company, Inc.

China Aoxing Pharmaceutical Company, Inc. (OTCBB: [ CAXG ]) is a pharmaceutical company located in China specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. It has a strategic alliance with American Oriental Bioengineering, Inc. (NYSE: [ AOB ]) to develop and market various narcotic drugs in China. Headquartered in Shijiazhuang City, the pharmaceutical capital of China, outside of Beijing, China Aoxing has China's largest and the most advanced manufacturing facility for highly regulated narcotic medicines, addressing a very under-served and fast-growing market in China. Its facility is one of the few GMP facilities licensed for narcotics medicines. The Company is working closely with the Chinese government and SFDA to assure the strictly regulated availability to medical professionals of its narcotic drugs and pain medicines throughout China.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-KSB for the year ended June 30, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.